Chronic hepatitis C is one of the most common human infectious diseases. Hepatitis C virus infection is the leading cause of cirrhosis and liver cancer, which affects an estimated 80 million patients with chronic hepatitis C virus (CVHC) worldwide and kills about 0.7 million people annually, according to WHO. The use of combination antiviral therapy makes it possible to achieve improvements in patients with chronic hepatitis C, however, some patients develop side effects during treatment, a special place among which is occupied by anemia.
The development of severe hematological syndromes in patients during combined antiviral therapy (CPT) for CHC is a very urgent problem [2, 4, 5]. Among the most dangerous complications in this case, one can especially single out CBT-associated anemia .